drugset / Trial / NCT00959933

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

NCT00959933

Phase 1 Completed 24 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.

Timeline

Start
2001-04
Primary completion
2001-05
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 200 mg